We are evaluating the safety and effectiveness of NEXAGON (Lufepirsen Ophthalmic Gel) for individuals with persistent corneal epithelial defects. The study aims to see if it helps heal the cornea better than a placebo.
We are testing the new medication tozorakimab in patients hospitalized for viral lung infections requiring oxygen. The goal is to see if it can help prevent serious complications compared to a placebo.
We are studying a new medication for people with moderate to severe plaque psoriasis. The goal is to see if it works better than a placebo in reducing symptoms.
We are evaluating the long-term health effects of gene-modified cells in participants, especially children and adolescents. This includes monitoring for serious side effects and overall growth and development.
We are studying a new treatment called iptacopan for people with generalized Myasthenia Gravis to see if it helps improve daily activities and muscle strength. The trial will also assess the safety of this treatment compared to a placebo.
We are testing a new treatment called povetacicept for individuals with autoimmune cytopenias. The study aims to evaluate its safety and effectiveness in managing this condition.
We are investigating a new drug called ISB 2001 for patients with relapsed or refractory multiple myeloma. This trial aims to see how well it works in treating this challenging condition.
We are testing a new combination therapy of albumin and enoxaparin for patients with decompensated cirrhosis at high risk of complications. The study aims to assess safety and explore how this treatment may affect the disease.
We are investigating the safety and effects of Leucettinib-21 in healthy individuals and patients with Down Syndrome and Alzheimer’s. This study aims to understand how the drug works in different populations.
We are comparing monthly versus daily vitamin D supplements to see which is more effective in raising vitamin D levels in obese children and teens. The study also looks at safety and how well participants follow the treatment.
We are studying the effectiveness of two pain relief methods after laparoscopic colorectal surgery. Our goal is to find out which method reduces opioid use and improves recovery.
We are testing a new drug for patients with advanced or metastatic solid tumors that have the KRAS G12D mutation. The study aims to understand the safety and dosage of this treatment.
We are investigating a new imaging method to help classify prostate cancer grades in men with localized, untreated disease. This study aims to assess the safety and effectiveness of this non-invasive technique.
We are studying a new intravenous treatment for adults with chronic immune thrombocytopenia to see if it can increase platelet counts and reduce bleeding. This trial will help us understand how well this treatment works and its safety.
We are studying whether intratumoral injections of Daromun can help patients with Stage IIIB/C melanoma live longer and reduce the chance of cancer returning after surgery. This trial compares the new treatment to standard surgery and therapy.
We are investigating the safety and effectiveness of a new oral medication combined with another treatment for adults with advanced or metastatic hormone receptor-positive breast cancer. This study aims to find better treatment options for patients facing this condition.
We are studying new treatments for interstitial lung disease in people with scleroderma to see if they improve lung function and overall health compared to a placebo.
We are studying whether inducing labor at home is as safe and effective as doing it in a hospital. We want to understand the costs and experiences of women and healthcare staff in both settings.
We are studying the safety and effectiveness of divarasib combined with pembrolizumab and chemotherapy in patients with untreated advanced lung cancer that has a KRAS G12C mutation. This research aims to find the best dose and treatment approach.
We are studying a new treatment for children and young adults with blood cancers and solid tumors. The trial aims to assess its safety and how well it may work in these young patients.